PARP inhibitors are a group of pharmacological inhibitors of the enzyme polymerase ADP ribosome (PARP).They are developed for multiple indications.PARP inhibitors can enhance the efficacy of radiotherapy, alkalization agents and platinum-based chemotherapy by inhibiting DNA damage repair and promoting apoptosis of tumor cells. Parp (Poly Adp-Ribose Polymerase) inhibitors is very effective in treating solid tumors and other diseases.Such as advanced ovarian cancer, fallopian tube cancer and primary peritoneal cancer.
Market Analysis and Insights: Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market
In 2019, the global PARP (Poly ADP-ribose Polymerase) Inhibitors market size was US$ 2178 million and it is expected to reach US$ 16180 million by the end of 2026, with a CAGR of 32.8% during 2021-2026.
Global PARP (Poly ADP-ribose Polymerase) Inhibitors Scope and Market Size
PARP (Poly ADP-ribose Polymerase) Inhibitors market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global PARP (Poly ADP-ribose Polymerase) Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the PARP (Poly ADP-ribose Polymerase) Inhibitors market is segmented into Olaparib, Talazoparib, etc.
Segment by Application, the PARP (Poly ADP-ribose Polymerase) Inhibitors market is segmented into Ovarian Cancer, Breast Cancer, Other, etc.
Regional and Country-level Analysis
The PARP (Poly ADP-ribose Polymerase) Inhibitors market is analysed and market size information is provided by regions (countries).
The key regions covered in the PARP (Poly ADP-ribose Polymerase) Inhibitors market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.

Competitive Landscape

and PARP (Poly ADP-ribose Polymerase) Inhibitors Market Share Analysis
PARP (Poly ADP-ribose Polymerase) Inhibitors market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in PARP (Poly ADP-ribose Polymerase) Inhibitors business, the date to enter into the PARP (Poly ADP-ribose Polymerase) Inhibitors market, PARP (Poly ADP-ribose Polymerase) Inhibitors product introduction, recent developments, etc.
The major vendors include AbbVie, Pfizer, AstraZeneca, GlaxoSmithKline, Clovis Oncology, Everest Pharmaceuticals, etc.

This report focuses on the global PARP (Poly ADP-ribose Polymerase) Inhibitors status, future forecast, growth opportunity, key market and key players. The study objectives are to present the PARP (Poly ADP-ribose Polymerase) Inhibitors development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

AbbVie
Pfizer
AstraZeneca
GlaxoSmithKline
Clovis Oncology
Everest Pharmaceuticals
...

Market segment by Type, the product can be split into

Olaparib
Talazoparib

Market segment by Application, split into

Ovarian Cancer
Breast Cancer
Other

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:

To analyze global PARP (Poly ADP-ribose Polymerase) Inhibitors status, future forecast, growth opportunity, key market and key players.
To present the PARP (Poly ADP-ribose Polymerase) Inhibitors development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of PARP (Poly ADP-ribose Polymerase) Inhibitors are as follows:
History Year: 2015-2019

Base Year:

2019

Estimated Year:

2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.